The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia
Abstract
The role of lipids is essential in any phase of the atherosclerotic process, which is considered a chronic lipid-related and inflammatory condition. The traditional lipid profile (including the evaluation of total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein) is a well-established tool to assess the risk of atherosclerosis and as such has been widely used as a pillar of cardiovascular disease prevention and as a target of pharmacological treatments in clinical practice over the last decades. However, other non-traditional lipids have emerged as possible alternative predictors of cardiometabolic risk in addition to traditional single or panel lipids, as they better reflect the overall interaction between lipid/lipoprotein fractions. Therefore, this review deals with the lipid involvement characterizing the pathophysiology of atherosclerosis, discussing some recently proposed non-traditional lipid indices and, in the light of available knowledge, their actual potential as new additive tools to better stratify cardiovascular risk in patients with hyperlipidemia as well as possible therapeutic targets in the clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871 · cited 1×
“In addition, TG-rich lipoproteins may both upregulate proinflammatory cytokines, adhesion molecules, and prothrombotic factors in ECs and enhance the recruitment and activation of monocytes, promoting the development of foam cells [93,101,102].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Boekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease
Castañer, O., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, Á., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Estruch, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.008 · Cited by 540
Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses
Fernández-Macías, J. C., Ochoa-Martínez, A. C., Varela-Silva, J. A., & Pérez-Maldonado, I. N. (2019) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.08.009 · Cited by 458
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Research works printed but not linked: 96
- Ralapanawa, 2021, Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review, J. Epidemiol. Glob. Health, 11, 169, 10.2991/jegh.k.201217.001 · DOI · Paper page
- Wilson, 2022, The intracellular signaling pathways governing macrophage activation and function in human atherosclerosis, Biochem. Soc. Trans, 50, 1673, 10.1042/BST20220441 · DOI
- Jakubiak, G.K., Pawlas, N., Cieślar, G., and Stanek, A. (2021). Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes. Int. J. Environ. Res. Public Health, 18. · DOI
- Poder, T.G., Erraji, J., Coulibaly, L.P., and Koffi, K. (2017). Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost-benefit analysis. PLoS ONE, 12. · DOI
- Minelli, 2020, Reflections on Atherosclerosis: Lesson from the Past and Future Research Directions, J. Multidiscip. Healthc., 13, 621, 10.2147/JMDH.S254016 · DOI
- Ross, 1999, Atherosclerosis—An Inflammatory Disease, N. Engl. J. Med., 340, 115, 10.1056/NEJM199901143400207 · DOI · Paper page
- Li, 2022, Recent Advance in Treatment of Atherosclerosis: Key Targets and Plaque-Positioned Delivery Strategies, J. Tissue Eng., 13, 20417314221088508, 10.1177/20417314221088509 · DOI
- Pirillo, 2018, The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis, Curr. Atheroscler. Rep., 20, 1, 10.1007/s11883-018-0715-0 · DOI
- Barzi, 2005, A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region, Ann. Epidemiol., 15, 405, 10.1016/j.annepidem.2005.01.005 · DOI
- Malekmohammad, K., Sewell, R.D., and Rafieian-Kopaei, M. (2019). Antioxidants and Atherosclerosis: Mechanistic Aspects. Biomolecules, 9. · DOI · Paper page
- Sies, 2005, Nutritional, Dietary and Postprandial Oxidative Stress, J. Nutr., 135, 969, 10.1093/jn/135.5.969 · DOI · Paper page
- Venugopal, S.K., Anoruo, M., and Jialal, I. (2022, December 15). Biochemistry, Low Density Lipoprotein. Available online: https://europepmc.org/article/NBK/nbk500010.
- Gleissner, 2007, Effects of Native and Modified Low-Density Lipoproteins on Monocyte Recruitment in Atherosclerosis, Hypertension, 50, 276, 10.1161/HYPERTENSIONAHA.107.089854 · DOI
- Formoso, 2016, Physiology and Pathophysiology of OxLDL Uptake by Vascular Wall Cells in Atherosclerosis, Vascul. Pharmacol., 84, 1, 10.1016/j.vph.2016.05.013 · DOI · Paper page
- Zakiev, 2016, Lipid Composition of Circulating Multiple-Modified Low Density Lipoprotein, Lipids Health Dis., 15, 1, 10.1186/s12944-016-0308-2 · DOI
- Orekhov, 2017, Circulating Desialylated Low Density Lipoprotein, Cor. Vasa., 59, e149, 10.1016/j.crvasa.2016.10.003 · DOI
- Poznyak, A.V., Wu, W.-K., Melnichenko, A.A., Wetzker, R., Sukhorukov, V., Markin, A.M., Khotina, V.A., and Orekhov, A.N. (2020). Signaling Pathways and Key Genes Involved in Regulation of Foam Cell Formation in Atherosclerosis. Cells, 9. · DOI
- Malekmohammad, 2021, Role of Lipid Accumulation and Inflammation in Atherosclerosis: Focus on Molecular and Cellular Mechanisms, Front. Cardiovasc. Med., 8, 707529, 10.3389/fcvm.2021.707529 · DOI · Paper page
- Villegas, 2012, Electronegative Low-Density Lipoprotein. A Link between Apolipoprotein B Misfolding, Lipoprotein Aggregation and Proteoglycan Binding, Curr. Opin. Lipidol., 23, 479, 10.1097/MOL.0b013e328357c933 · DOI
- Maiolino, 2013, The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts, Mediat. Inflamm., 2013, 714653, 10.1155/2013/714653 · DOI · Paper page
- Summerhill, V.I., Grechko, A.V., Yet, S.-F., Sobenin, I.A., and Orekhov, A.N. (2019). The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. Int. J. Mol. Sci., 20. · DOI · Paper page
- Mofidi, 2001, Association between Plaque Instability, Angiogenesis and Symptomatic Carotid Occlusive Disease, J. Br. Surg., 88, 945, 10.1046/j.0007-1323.2001.01823.x · DOI · Paper page
- Hansson, 2006, Inflammation and Atherosclerosis, Annu. Rev. Pathol. Mech. Dis., 1, 297, 10.1146/annurev.pathol.1.110304.100100 · DOI · Paper page
- Abdolmaleki, 2019, Atherosclerosis and Immunity: A Perspective, Trends Cardiovasc. Med., 29, 363, 10.1016/j.tcm.2018.09.017 · DOI
- Pirillo, 2013, LOX-1, OxLDL, and Atherosclerosis, Mediators Inflamm., 2013, 152786, 10.1155/2013/152786 · DOI · Paper page
- Nickel, 2009, OxLDL Uptake by Dendritic Cells Induces Upregulation of Scavenger-Receptors, Maturation and Differentiation, Atherosclerosis, 205, 442, 10.1016/j.atherosclerosis.2009.01.002 · DOI
- Linton, M.F., Yancey, P.G., Davies, S.S., Jerome, W.G., Linton, E.F., Song, W.L., Doran, A.C., and Vickers, K.C. (2019). The Role of Lipids and Lipoproteins in Atherosclerosis. Endotext Internet, Available online: https://www.ncbi.nlm.nih.gov/books/NBK343489/.
- Millette, 2006, Platelet-Derived Growth Factor-BB Transactivates the Fibroblast Growth Factor Receptor to Induce Proliferation in Human Smooth Muscle Cells, Trends Cardiovasc. Med., 16, 25, 10.1016/j.tcm.2005.11.003 · DOI
- Nakahara, 2017, Coronary Artery Calcification: From Mechanism to Molecular Imaging, JACC Cardiovasc. Imaging, 10, 582, 10.1016/j.jcmg.2017.03.005 · DOI · Paper page
- Clemente, 2020, Vascular and Valvular Calcification Biomarkers, Adv. Clin. Chem., 95, 73, 10.1016/bs.acc.2019.08.002 · DOI
- Lippi, 2011, Arterial Thrombus Formation in Cardiovascular Disease, Nat. Rev. Cardiol., 8, 502, 10.1038/nrcardio.2011.91 · DOI · Paper page
- Ouweneel, 2016, Lipoproteins as Modulators of Atherothrombosis: From Endothelial Function to Primary and Secondary Coagulation, Vascul. Pharmacol., 82, 1, 10.1016/j.vph.2015.10.009 · DOI
- Mućka, S., Miodońska, M., Jakubiak, G.K., Starzak, M., Cieślar, G., and Stanek, A. (2022). Endothelial Function Assessment by Flow-Mediated Dilation Method: A Valuable Tool in the Evaluation of the Cardiovascular System. Int. J. Environ. Res. Public Health, 19. · DOI
- Papagiouvanni, 2022, Endothelial and microvascular function in liver cirrhosis: An old concept that needs re-evaluation?, Ann. Gastroenterol., 35, 471
- Goldberg, 2011, Triglycerides and Heart Disease: Still a Hypothesis?, Arterioscler. Thromb. Vasc. Biol., 31, 1716, 10.1161/ATVBAHA.111.226100 · DOI · Paper page
- Płaczkowska, S., Sołkiewicz, K., Bednarz-Misa, I., and Kratz, E.M. (2022). Atherogenic Plasma Index or Non-High-Density Lipoproteins as Markers Best Reflecting Age-Related High Concentrations of Small Dense Low-Density Lipoproteins. Int. J. Mol. Sci., 23. · DOI
- Guo, 2020, The Sensibility of the New Blood Lipid Indicator Atherogenic Index of Plasma (AIP) in Menopausal Women with Coronary Artery Disease, Lipids Health Dis., 19, 1, 10.1186/s12944-020-01208-8 · doi:10.1186/s12944-020-01208-8
- Tian, 2019, Targeting LOX-1 in atherosclerosis and vasculopathy: Current knowledge and future perspectives, Ann. N. Y. Acad. Sci., 1443, 34, 10.1111/nyas.13984 · DOI
- Varghese, 2021, Pathological Crosstalk Between Oxidized LDL and ER Stress in Human Diseases: A Comprehensive Review, Front. Cell Dev. Biol., 9, 674103, 10.3389/fcell.2021.674103 · DOI
- Zingg, J.M., Vlad, A., and Ricciarelli, R. (2021). Oxidized LDLs as Signaling Molecules. Antioxidants, 10. · DOI
- Gao, 2017, Association Between Circulating Oxidized LDL and Atherosclerotic Cardiovascular Disease: A Meta-analysis of Observational Studies, Can. J. Cardiol., 33, 1624, 10.1016/j.cjca.2017.07.015 · DOI
- Gao, 2018, Circulating Oxidized Low-Density Lipoprotein Levels Independently Predict 10-Year Progression of Subclinical Carotid Atherosclerosis: A Community-Based Cohort Study, J. Atheroscler Thromb., 25, 1032, 10.5551/jat.43299 · DOI
- Jamialahmadi, 2022, The Effects of Statin Therapy on Oxidized LDL and Its Antibodies: A Systematic Review and Meta-Analysis, Oxid. Med. Cell Longev., 2022, 7850659, 10.1155/2022/7850659 · DOI
- Banerjee, 2019, Beyond LDL-c: The importance of serum oxidized LDL in predicting risk for type 2 diabetes in the middle-aged Asian Indians, Diabetes Metab. Syndr., 13, 206, 10.1016/j.dsx.2018.08.036 · DOI
- Nishi, 2002, Oxidized LDL in carotid plaques and plasma associates with plaque instability, Arterioscler. Thromb. Vasc. Biol., 22, 1649, 10.1161/01.ATV.0000033829.14012.18 · DOI · Paper page
- Hartley, 2019, Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis—Novel insights and future directions in diagnosis and therapy, Trends Cardiovasc. Med., 29, 22, 10.1016/j.tcm.2018.05.010 · DOI · Paper page
- Jakubiak, G.K., Cieślar, G., and Stanek, A. (2022). Nitrotyrosine, Nitrated Lipoproteins, and Cardio-vascular Dysfunction in Patients with Type 2 Diabetes: What Do We Know and What Remains to Be Explained?. Antioxidants, 11. · DOI
- Lee, C.-K., Liao, C.-W., Meng, S.-W., Wu, W.-K., Chiang, J.-Y., and Wu, M.-S. (2021). Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis. Biomedicines, 9. · DOI
- Ali, 2012, Cardiovascular Disease Risk Reduction by Raising HDL Cholesterol–Current Therapies and Future Opportunities, Br. J. Pharmacol., 167, 1177, 10.1111/j.1476-5381.2012.02081.x · DOI · Paper page
- Brea, 2019, Non-HDL Cholesterol as a Therapeutic Goal, Clin. Investig. Arterioscler., 31, 28
- Rana, 2012, The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease, Curr. Atheroscler. Rep., 14, 130, 10.1007/s11883-011-0224-x · DOI
- Brunner, 2019, Application of Non-HDL Cholesterol for Population-Based Cardiovascular Risk Stratification: Results from the Multinational Cardiovascular Risk Consortium, Lancet, 394, 2173, 10.1016/S0140-6736(19)32519-X · DOI · Paper page
- Wang, 2021, Non–High-Density Lipoprotein Cholesterol Predicts Adverse Outcomes in Acute Ischemic Stroke, Stroke, 52, 2035, 10.1161/STROKEAHA.120.030783 · DOI
- Li, 2011, Serum Non-High-Density Lipoprotein Cholesterol Concentration and Risk of Death from Cardiovascular Diseases among US Adults with Diagnosed Diabetes: The Third National Health and Nutrition Examination Survey Linked Mortality Study, Cardiovasc. Diabetol., 10, 1, 10.1186/1475-2840-10-46 · DOI
- Liu, 2017, Meta-Analysis of Serum Non-High-Density Lipoprotein Cholesterol and Risk of Coronary Heart Disease in the General Population, Clin. Chim. Acta, 471, 23, 10.1016/j.cca.2017.05.006 · DOI
- Duncan, 2019, Trajectories of Blood Lipid Concentrations over the Adult Life Course and Risk of Cardiovascular Disease and All-cause Mortality: Observations from the Framingham Study over 35 Years, J. Am. Heart Assoc., 8, e011433, 10.1161/JAHA.118.011433 · DOI
- Peterson, 2015, Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease, Circulation, 131, 451, 10.1161/CIRCULATIONAHA.114.012477 · DOI · Paper page
- Liao, 2017, Prognostic Value of Non-High-Density Lipoprotein Cholesterol for Mortality in Patients with Coronary Heart Disease: A Systematic Reviewemnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the Copenhagen General Population Study and Meta-Analysis, Int. J. Cardiol., 227, 950, 10.1016/j.ijcard.2016.10.106 · DOI
- We, 2019, Associations of non-high-density are effective lipoprotein cholesterol, triglycerides and the total cholesterol/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population, Hypertens. Res., 42, 1223, 10.1038/s41440-019-0251-5 · DOI
- Parhofer, 2022, New targets for treating hypertriglyceridemia, Curr. Opin. Endocrinol. Diabetes Obes., 29, 106, 10.1097/MED.0000000000000714 · DOI
- Carr, 2019, Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment, Pathology, 51, 148, 10.1016/j.pathol.2018.11.006 · DOI · Paper page
- Hoogeveen, 2021, Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation, Clin. Chem., 67, 143, 10.1093/clinchem/hvaa252 · DOI · Paper page
- 2021, Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: Current status and treatments, Curr. Opin. Endocrinol. Diabetes Obes., 28, 85, 10.1097/MED.0000000000000619 · DOI
- Barter, 2006, Apo B versus Cholesterol in Estimating Cardiovascular Risk and in Guiding Therapy: Report of the Thirty-person/Ten-country Panel, J. Intern. Med., 259, 247, 10.1111/j.1365-2796.2006.01616.x · DOI · Paper page
- Robinson, 2012, Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials, Am. J. Cardiol., 110, 1468, 10.1016/j.amjcard.2012.07.007 · DOI
- Hodkinson, 2022, Comparative Effectiveness of Statins on Non-High Density Lipoprotein Cholesterol in People with Diabetes and at Risk of Cardiovascular Disease: Systematic Review and Network Meta-Analysis, BMJ, 376, e067731-74
- Pencina, 2019, Trajectories of Non–HDL Cholesterol across Midlife: Implications for Cardiovascular Prevention, J. Am. Coll. Cardiol., 74, 70, 10.1016/j.jacc.2019.04.047 · DOI
- Armstrong, 2021, Association of Non-High-Density Lipoprotein Cholesterol Measured in Adolescence, Young Adulthood, and Mid-Adulthood With Coronary Artery Calcification Measured in Mid-Adulthood, JAMA Cardiol., 6, 661, 10.1001/jamacardio.2020.7238 · DOI
- Castelli, 1983, Summary Estimates of Cholesterol Used to Predict Coronary Heart Disease, Circulation, 67, 730, 10.1161/01.CIR.67.4.730 · DOI · Paper page
- Pallardo, 2009, Lipoprotein Ratios: Physiological Significance and Clinical Usefulness in Cardiovascular Prevention, Vasc. Health Risk Manag., 5, 757
- Albrektsen, 2017, Risk of incident myocardial infarction by gender: Interactions with serum lipids, blood pressure and smoking. The Tromsø Study 1979–2012, Atherosclerosis, 261, 52, 10.1016/j.atherosclerosis.2017.04.009 · DOI
- Langer, 2003, Sex and time differences in the associations of non-high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (The Rancho Bernardo Study), Am. J. Cardiol., 91, 1311, 10.1016/S0002-9149(03)00319-9 · DOI
- Kouvari, M., Panagiotakos, D.B., Chrysohoou, C., Georgousopoulou, E.N., Tousoulis, D., and Pitsavos, C. (2020). Sex-Related Differences of the Effect of Lipoproteins and Apolipoproteins on 10-Year Cardiovascular Disease Risk; Insights from the ATTICA Study (2002–2012). Molecules, 25. · DOI
- Vigna, 2022, Insulin Resistance and Cardiometabolic Indexes: Comparison of Concordance in Working-Age Subjects with Overweight and Obesity, Endocrine, 77, 1, 10.1007/s12020-022-03087-8 · DOI
- Lemieux, 2001, Total Cholesterol/HDL Cholesterol Ratio vrequiring extensive reorganization and re-writings LDL Cholesterol/HDL Cholesterol Ratio as Indices of Ischemic Heart Disease Risk in Men: The Quebec Cardiovascular Study, Arch. Intern. Med., 161, 2685, 10.1001/archinte.161.22.2685 · DOI · Paper page
- Bhardwaj, 2013, Atherogenic Index of Plasma, Castelli Risk Index and Atherogenic Coefficient-New Parameters in Assessing Cardiovascular Risk, Int. J. Pharm. Biol. Sci., 3, 359
- Nair, 2009, Association of Total Cholesterol/High-density Lipoprotein Cholesterol Ratio with Proximal Coronary Atherosclerosis Detected by Multislice Computed Tomography, Prev. Cardiol., 12, 19, 10.1111/j.1751-7141.2008.00011.x · DOI
- Varbo, 2015, Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population, Clin. Chem., 61, 533, 10.1373/clinchem.2014.234146 · DOI · Paper page
- Liu, 2021, Association of Triglyceride-Rich Lipoprotein-Cholesterol with Recurrent Cardiovascular Events in Statin-Treated Patients According to Different Inflammatory Status, Atherosclerosis, 330, 29, 10.1016/j.atherosclerosis.2021.06.907 · DOI
- Fujioka, 2009, Remnant lipoproteins as strong key particles to atherogenesis, J. Atheroscler. Thromb., 16, 145, 10.5551/jat.E598 · DOI · Paper page
- Li, 2021, Atherogenic index of plasma as predictors for metabolic syndrome, hy-pertension and diabetes mellitus in Taiwan citizens: A 9-year longitudinal study, Sci. Rep., 11, 9900, 10.1038/s41598-021-89307-z · DOI · Paper page
- Khakurel, 2018, Atherogenic Index of Plasma in Postmenopausal Women, J. Nepal. Health Res. Counc., 16, 175, 10.33314/jnhrc.v16i2.1570 · doi:10.33314/jnhrc.v16i2.1570
- Cai, 2017, The atherogenic index of plasma is a strong and independent predictor for coronary artery dis-ease in the Chinese Han population, Medicine (Baltimore), 96, e8058, 10.1097/MD.0000000000008058 · DOI · Paper page
- Hartopo, 2016, Low Plasma Atherogenic Index Associated with Poor Prognosis in Hospitalized Patients with Acute Myocardial Infarction, Acta Medica Indones., 48, 106
- Shin, H.R., Song, S., Cho, J.A., and Ly, S.Y. (2022). Atherogenic Index of Plasma and Its Association with Risk Factors of Coronary Artery Disease and Nutrient Intake in Korean Adult Men: The 2013–2014 KNHANES. Nutrients, 14. · DOI
- Li, 2018, Atherogenic Index in Type 2 Diabetes and Its Relationship with Chronic Microvascular Complications, Int. J. Endocrinol., 2018, 1765835, 10.1155/2018/1765835 · DOI
- Qin, 2020, The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: Results from an observational cohort study in China, Cardiovasc. Diabetol., 19, 23, 10.1186/s12933-020-0989-8 · DOI
- Zhou, 2021, The Atherogenic Index of Plasma: A Powerful and Reliable Predictor for Coronary Artery Disease in Patients with Type 2 Diabetes, Angiology, 72, 934, 10.1177/00033197211012129 · DOI
- Mangalesh, 2022, Atherogenic index of plasma predicts coronary artery disease severity and major adverse cardiac events in absence of conventional risk factors, Coron. Artery Dis., 33, 523, 10.1097/MCA.0000000000001166 · DOI
- Shui, 2022, Association of Atherogenic Index of Plasma With Angiographic Progression in Patients With Suspected Coronary Artery Disease, Angiology, 1, 33197221080911
- Zhan, Y., Xu, T., and Tan, X. (2016). Two parameters reflect lipid-driven inflammatory state in acute coronary syndrome: Atherogenic index of plasma, neutrophil-lymphocyte ratio. BMC Cardiovasc. Disord., 16. · DOI
- Sniderman, 2011, A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk, Circ. Cardiovasc. Qual. Outcomes, 4, 337, 10.1161/CIRCOUTCOMES.110.959247 · DOI · Paper page
- McLaughlin, 2005, Is There a Simple Way to Identify Insulin-Resistant Individuals at Increased Risk of Cardiovascular Disease?, Am. J. Cardiol., 96, 399, 10.1016/j.amjcard.2005.03.085 · DOI · Paper page
- Sirtori, 2001, Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: The Limone sul Garda study, Circulation, 103, 1949, 10.1161/01.CIR.103.15.1949 · DOI · Paper page
- Bielicki, 2002, Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I, Biochemistry, 41, 2089, 10.1021/bi011716p · DOI
- Zhang, 2020, Trends in LDL and Non-HDL Levels with Age, Aging Dis., 11, 1046, 10.14336/AD.2019.1025 · DOI
Metadata
- Authors
- Gaggini, M., Gorini, F., & Vassalle, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-12-21
- Volume
- 24
- Issue
- 1
- Pages
- 75
- ISSN
- 1422-0067
- Cited by
- 163
- References
- 24
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia. https://app.cochat.ai/papers/10.3390/ijms24010075
- The paper
- Gaggini, M., Gorini, F., & Vassalle, C. (2022). Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24010075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.